Glaukos (GKOS) Q2 2026: Revenue Crushes Estimates by 23% on iDose Surge
As seen on the 24/7 Wall St. homepage on July 29, 2026.
Glaukos crushed revenue expectations by 23% as iDose TR crossed $74 million in sales and Epioxa launched with $11 million in early traction, spurring the company to raise full-year guidance by $45 million to $680-700 million.
Continue ReadingShow less
Glaukos reported Q2 2026 revenue of $185.61 million, blowing past the $150.97 million consensus estimate by roughly 23%. The quarter was driven by iDose TR, which crossed $74 million in sales, and the newly launched Epioxa, which added $11 million in early commercial traction. On the bottom line, the company posted a loss of $0.14 per share against an estimated loss of $0.22, a beat of about 37%.
The strength of the quarter gave management enough confidence to raise full-year revenue guidance by $45 million, setting the new outlook at $680 to $700 million. That upward revision reflects the acceleration visible in the revenue trend: quarterly sales have climbed from $95.69 million in Q2 2024 to $185.61 million in Q2 2026, a near-doubling over two years.
Sponsored
Are You Ready To Retire, Or Years Behind?
Most Americans suspect they're behind on retirement and never find out. Advisor.com's free matching tool pairs you in about three minutes with a vetted fiduciary advisor who can help you with investing, taxes, retirement, estate planning, and more. No minimums. No sales call. Find out where you stand.
Shares reacted sharply to the after-hours filing, jumping from around $161 to approximately $175 in the minutes following the release. Investors will be watching whether Epioxa's early momentum holds and whether iDose TR can sustain its growth trajectory as the company pushes toward its raised full-year targets.
Mentioned: GKOS